The U.S. Food and Drug Administration awarded 12 clinical trial research grants to develop new treatments for a number of rare diseases, including advanced pancreatic cancer, head and neck squamous carcinoma, acute myeloid leukemia, Stargardt disease, and others.
These $18 million in grants were awarded to researchers across the United States through the Orphan Products Clinical Trials Grants Program, which is designed to encourage the development of drugs, biologics, and medical devices to treat or prevent rare diseases, with a goal of FDA-approval.
Grant applications were reviewed and evaluated by more than 100 rare disease experts, including representatives from the medical field, the National Institutes of Health (NIH), and the FDA. More than 600 new clinical studies have been funded through the Orphan Products Clinical Trials Grants Program since 1983. About a third of the new grants are geared toward cancer research.
Sourced from: FDA